Precipio (PRPO) Expected to Release Quarterly Earnings on Tuesday

Precipio (NASDAQ:PRPO) is expected to be posting its Q3 2026 results after the market closes on Tuesday, November 10th. Analysts expect the company to post earnings of ($2.00) per share and revenue of $1.68 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 10, 2026 at 5:00 PM ET.

Precipio (NASDAQ:PRPO) last issued its quarterly earnings data on Friday, August 14th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($2.00) by $1.88. Precipio had a negative net margin of 4.47% and a negative return on equity of 8.49%. The business had revenue of $7.02 million for the quarter, compared to the consensus estimate of $1.68 million.

Precipio Stock Up 0.2%

Shares of NASDAQ PRPO opened at $18.62 on Friday. The company has a current ratio of 1.77, a quick ratio of 1.56 and a debt-to-equity ratio of 0.06. Precipio has a 12 month low of $17.79 and a 12 month high of $33.63. The firm has a market capitalization of $33.33 million, a PE ratio of -29.09 and a beta of 1.45. The firm has a fifty day simple moving average of $23.41 and a two-hundred day simple moving average of $24.79.

Analysts Set New Price Targets

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Precipio in a research note on Thursday, October 15th. One equities research analyst has rated the stock with a Sell rating. According to data from MarketBeat, Precipio has an average rating of “Sell”.

About Precipio

Precipio, Inc (NASDAQ: PRPO) is a biotechnology and medical diagnostics company focused on improving the diagnosis of cancer and other complex diseases. The company combines specialized pathology expertise with laboratory testing and diagnostic technologies intended to help physicians identify disease accurately and support treatment decisions.

Precipio provides clinical laboratory services in areas including hematopathology, cytogenetics and molecular diagnostics. Its work is particularly focused on blood cancers and other hematologic disorders, where accurate classification can be challenging.